José A. Stoute - Concepedia

Author

José A. Stoute

Walter Reed Army Institute of Research ORCID

Also Known As

J A Stoute, J. A. STOUTE, J. A. Stoute, J.A. Stoute, JOSÉ A. STOUTE, JOSË A. STOUTE, Jose A Stoute, Jose A. Stoute, Jose Stoute, Jose A. Stoute

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Walter Reed Army Institute of Research Kenya Medical Research Institute United States Army Medical Research Directorate - Africa Pennsylvania State University Uniformed Services University of the Health Sciences

About

José A. Stoute is an author at Walter Reed Army Institute of Research specializing in medicine, immunology, and malaria.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	782
2	Natural Sciences	2	2	86
3	Health Sciences	1	1	32
4	Public Health	1	1	80
5	Allergy	1	1	36

José A. Stoute

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against<i>Plasmodium falciparum</i><i>Malaria</i> José A. Stoute, M. Slaoui, D. Gray Heppner, New England Journal of Medicine	1997	874
Protection of Humans against Malaria by Immunization with Radiation‐Attenuated<i>Plasmodium falciparum</i>Sporozoites Stephen L. Hoffman, Lucy M. L. Goh, Thomas Luke, The Journal of Infectious Diseases	2002	686
Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine José A. Stoute, Kent E. Kester, Urszula Krzych, The Journal of Infectious Diseases	1998	235
Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to <i>Plasmodium falciparum</i> Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ Peifang Sun, Robert Schwenk, Katherine White, The Journal of Immunology	2003	231
Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC‐Pf7, a Pox‐Vectored, Multiantigen, Multistage Vaccine Candidate for<i>Plasmodium falciparum</i>Malaria Christian F. Ockenhouse, P. Sun, David E. Lanar, The Journal of Infectious Diseases VaccinationVaccinologyVaccine DevelopmentCandidate Malaria VaccinesPhase I/iia Safety	1998	224
Red cell surface changes and erythrophagocytosis in children with severe Plasmodium falciparum anemia John Waitumbi, Malachi O. Opollo, Richard Muga, Blood	2000	197
Loss of Red Blood Cell–Complement Regulatory Proteins and Increased Levels of Circulating Immune Complexes Are Associated with Severe Malarial Anemia José A. Stoute, Alfred Odindo, Boaz O. Owuor, The Journal of Infectious Diseases	2003	119
<i>Plasmodium falciparum</i> antigenic variation. Mapping mosaic <i>var</i> gene sequences onto a network of shared, highly polymorphic sequence blocks Peter C. Bull, Caroline O. Buckee, Sue Kyes, Molecular Microbiology	2008	100
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya José A. Stoute, Joash Gombe, Mark R. Withers, Vaccine VaccinationVaccine TargetMalariaImmunologyParasite Genomics	2005	100
Complement Receptor 1 Is a Sialic Acid-Independent Erythrocyte Receptor of Plasmodium falciparum Carmenza Spadafora, Gordon A. Awandare, Karen M. Kopydlowski, PLoS Pathogens Complement SystemComplement Receptor 1Plasmodium FalciparumLethal Malaria ParasiteMalaria	2010	97

Page 1